Artiva Biotherapeutics (ARTV) announced the appointment of Subhashis Banerjee as chief medical officer. Banerjee was most recently disease area head for rheumatology and dermatology global development at Bristol Myers Squibb (BMY). Banerjee will succeed Thorsten Graef who will continue as a strategic advisor to the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTV:
- Promising Outlook for Artiva Biotherapeutics Amid Strategic Manufacturing and Regulatory Support
- Artiva Biotherapeutics Reports 2024 Financial Results
- Artiva Biotherapeutics: Strong Buy Rating Backed by Promising Pipeline and Financial Stability
- Artiva Biotherapeutics price target lowered to $20 from $23 at Cantor Fitzgerald